Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

• Main Authors: Stephanie Pepin (Author), Jean-François Nicolas (Author), Henryk Szymanski (Author), Isabel Leroux-Roels (Author), Thomas Schaum (Author), Marc Bonten (Author), Giancarlo Icardi (Author), Anju Shrestha (Author), Cynthia Tabar (Author), The QHD00011 study team (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60-64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalen...